Decoy Therapeutics Inc. Form 8-K Summary
Business context and reporting period
Decoy Therapeutics Inc. filed a Form 8-K dated September 22, 2026, with the transaction closing on September 23, 2026. The filing reports a warrant inducement transaction involving an existing holder of the Company’s Series A, Series B and Series C milestone-based common warrants issued June 29, 2026. The Company’s common stock trades on Nasdaq Capital Market under the symbol DCOY.
Transaction and key financial terms
- The holder exercised all Series B Milestone Warrants covering 1,184,434 common shares.
- The exercise price was reduced from $5.91 to $3.25 per share.
- The Company received approximately $3.85 million in aggregate gross proceeds, before placement agent fees and other expenses.
- Net proceeds are intended for working capital and general corporate purposes.
- The exercise price of the outstanding Series A and Series C Milestone Warrants was also reduced to $3.25 per share; other terms were not amended.
- The Company issued new unregistered warrants to purchase up to 2,368,868 common shares, equal to 200% of the shares underlying the exercised warrants.
- The New Warrants have a $3.25 exercise price, are immediately exercisable, expire five years after issuance, and include customary anti-dilution, cashless-exercise and 9.99% beneficial-ownership provisions.
Material changes versus the prior comparable period
This is a transaction-specific Form 8-K and does not provide comparative income statement, balance sheet or cash flow information. Relative to the previously outstanding warrants, the principal changes are the reduced exercise price, the cash exercise of the Series B warrants, and issuance of the New Warrants.
Guidance, outlook, risks and unusual items
- The Company must file a resale registration statement for the shares underlying the New Warrants within 15 calendar days after September 22, 2026, and use commercially reasonable efforts to make it effective within the required period.
- The Company agreed, subject to exceptions, not to issue common stock or common-stock equivalents or file a registration statement for 30 days after the Inducement Letter.
- Subject to exceptions, the Company also agreed not to enter into a variable-rate transaction until 180 days after the resale registration statement for the New Warrants becomes effective.
- The New Warrants and underlying shares were sold without registration under Section 4(a)(2) of the Securities Act to an investor represented to be accredited.
- The issuance and exercise of the New Warrants do not require stockholder approval. The Company issued a corrective press release clarifying this point and confirming immediate exercisability.
- Potential future dilution may result from exercise of the New Warrants and the repriced Series A and Series C Milestone Warrants.
Important facts for investors to verify
- Confirm the final net cash proceeds after placement agent fees and other transaction expenses; the filing provides only approximate gross proceeds.
- Review the filed Inducement Letter and New Warrant form for complete adjustment, cashless-exercise, ownership-limit and other provisions.
- Monitor the filing and effectiveness of the resale registration statement for the New Warrants.
- Assess the potential dilution from up to 2,368,868 New Warrant shares and the repriced Series A and Series C warrants.
- Review the Company’s subsequent financial filings for the effect of the proceeds on liquidity and working capital.